General Information
Version
6.5
Revision date
2024-01-25
Product name
4,4′-Dimethoxydiphenylamine
CAS No.
101-70-2
REACH No
A
Emergency telephone
+81 (3)4531-1145, +81 (0)3 4520 9637
Icons in SDS
Company Information
company name
Merck Ltd.
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H315, H319, H335, H351
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Skin irritation, (Category 2) H315: Causes skin irritation. Eye irritation, (Category 2) H319: Causes serious eye irritation. Carcinogenicity, (Category 2) H351: Suspected of causing cancer. Specific target organ toxicity - H335: May cause respiratory irritation. single exposure, (Category 3),
Signal word
Warning Warning
Hazard statements
H315 Causes skin irritation. H319 Causes serious eye irritation. H335 May cause respiratory irritation. H351 Suspected of causing cancer. H351 Suspected of causing cancer.
Precautionary statements
P201 Obtain special instructions before use. P302 + P352 IF ON SKIN: Wash with plenty of water. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P201 Obtain special instructions before use. P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Supplemental label elements
none Reduced Labeling (<= 125 ml) none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.